BioTime’s Renevia Succeeds in Pivotal European Facial Wasting Trial

(Reuters) – BioTime Inc said on Wednesday its Renevia system succeeded in meeting the main goal of a pivotal European trial for facial wasting associated with treatment for HIV, putting it on track to file for European approval this year. The 47 patients …
( read original story …)



Related